Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: A comparison of modeling approaches to estimate and extrapolate survival outcomes

Journal of Medical Economics

Volumn 19, Issue 6, 2016, Pages 630-644

  Goeree, Ron ^a,b   Villeneuve, Julie ^c   Goeree, Jeff ^a   Penrod, John R ^d   Orsini, Lucinda ^d   Monfared, Amir Abbas Tahami ^c,e  

^a Goeree Consulting   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Bristol Myers Squibb Canada   (Canada)

^d BRISTOL MYERS SQUIBB   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

Economic evaluation; Markov model; Nivolumab; Partitioned survival model; Squamous non small cell lung cancer; Structural uncertainty

Indexed keywords

DOCETAXEL; ERLOTINIB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADVANCED CANCER; ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG MONITORING; HEALTH STATUS; HUMAN; LONG TERM CARE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL RATE; CANCER GROWTH; CANCER MORTALITY; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE QUALITY; HIDDEN MARKOV MODEL; PARTITIONED SURVIVAL MODEL; SENSITIVITY ANALYSIS; SQUAMOUS NON SMALL CELL LUNG CANCER; STATISTICAL ANALYSIS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; DISEASE MANAGEMENT; ECONOMICS; HEALTH SERVICE; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MORTALITY; STATISTICAL MODEL; TERMINAL CARE; UTILIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; HEALTH SERVICES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MODELS, ECONOMETRIC; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; TAXOIDS; TERMINAL CARE;

EID: 84961209546     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2016.1151432     Document Type: Article

References (49)

1. World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012: Fact Sheet 2012. Lyon France 2012 http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp. Accessed October 1, 2015
2. Canadian Cancer Society. Lung cancer statistics 2015. Toronto, Ontario, Canada 2015 http://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region¼on. Accessed October 1, 2015
3. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Table 15.6: Cancer of the Lung and Bronchus (Invasive): age-adjusted SEER Incidence Rates by Year, Race and Sex 2012. Bethesda, MD, USA 2012 http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL¼15&pageSEL¼sect_15_table.06.html. Accessed October 1, 2015
4. Penrod JR, Korytowsky B, Petrilla A, et al. Survival of US medicare patients with advanced Non-Small Cell Lung Cancer (NSCLC) by Line of Therapy (abstract 6582). J Clin Oncol 2014;32 S5
5. Public Health Agency of Canada. The prevalence of chronic pain and pain-related interference in the Canadian population from 1994 to 1998. 2014. Ottawa, Ontario, Canada 2014 http://www.phac-aspc.gc.ca/publicat/hpcdp-pspmc/31-4/ar-04-eng.php. Accessed June 30, 2015
6. Leighl N. Treatment paradigms for patients with metastatic nonsmall- cell lung cancer: first-, second-, and third-line. Curr Oncol 2012;19(1 Suppl):S52–S58
7. National Comprehensive Care Network (NCCN). Guidelines for Nonsmall cell lung cancer v 7.2015. 2015. Fort Washington, PA, USA http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed October 1, 2015
8. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:S851
9. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253–63
10. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012;18:1167–76
11. Prince R, Atenafu E, Krzyzanowska M. Hospitalizations during systemic therapy for metastatic lung cancer: a systematic review of RealWorld vs clinical trial outcomes. JAMA Oncol. 2015;1(9):1333-1339. 2015;doi:10.1001/jamaoncol.2015.3440(online September 17, 2015):E1-E7.
12. Kulkarni S, Vella E, Coakley N, et al. The use of systemic treatment in the maintenance of patients with non-small cell lung cancer. Toronto, ON: Cancer Care Ontario, 2015. Program in Evidencebased Care Evidence-based Series No.: 7–22. 2015
13. Goffin J, Lacchetti C, Ellis PM, et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010;5:260–74
14. Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3488–515
15. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014;32:3673–9
16. Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014;25:1475–84
17. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32
18. Mandelblatt J, Fryback D, Weinstein M, et al. Assessing the effectiveness of health interventions. In: Gold M, Siegel J, Russell L, et al, eds. New York: Oxford University Press, 1996
19. Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - Extrapolation with patient level data. 2011 National Institute for Health and Clinical Excellence (NICE) Decision Support Unit: Sheffield, UK available at: http://www.nicedsu.org.uk/NICE%20DSU%20TSD%20Survival%20analysis.updated%20March%202013.v2.pdf
20. Latimer N. Survival analysis for economic evaluations alongside clinical trials—Extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. MDM 2013;33:743–54.
21. Royston P, Parmar M. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;21:2175–97
22. Coyle D, Coyle K. The inherent bias from using partitioned survival models in economic evaluation. Value Health 2014;17:A194
23. Beca J, Hoch J. Exlporing the impact of structural uncertainty in partitioned survvial models for oncology. Value Health 2014;17:A205–6
24. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–35
25. Grambsch T, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1993;81:515–26
26. Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, Chow L, Vokes E, Felip E, et al Nivolumab versus Docetaxel in Advanced Nonsquamous NonSmall-Cell Lung Cancer N Engl J Med 2015; 373(17):1627-1639
27. Chandra A, Vanderpuye-Orgle J, Summers N, et al. Indirect treatment comparison of relative efficacy and safety of nivolumab versus relevant comparator treatments among advanced non-small cell lung cancer patients of squamous cell receiving second-line or higher therapy. Los Angeles, CA: Precision Health Economics, 2015
28. Garassino M, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981–8
29. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies, 3rd edn. Ottawa, Ontario: CADTH; 2006. https://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accesed October 1, 2015
30. Canadian Agency for Drugs and Technologies in Health (CADTH). Addendum to the Canadian Agency for Drugs and Technologies in health guidelines for the economic evaluation of health technologies: specific guidance for oncology products. Ottawa, Ontario: CADTH; 2009. https://www.cadth.ca/sites/default/files/pdf/H0405_Guidance:for_Oncology_Prodcuts_gr_e.pdf. Accessed October 1, 2015
31. Statistics Canada. Consumer Price Index, health and personal care, by province (monthly). Government of Canada, 2015. Ottawa, Ontario, Canada http://www.statcan.gc.ca/tables-tableaux/sum-som/101/cst01/cpis13a-eng.htm. Accessed June 30, 2015
32. Ontario Ministry of Health and Long-Term Care. Schedule of benefits for physician services under the Health Insurance Act 2015. Toronto, Ontario, Canada 2015 http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.html. Accessed June 30, 2015
33. Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-Life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care 2011;27:79–88
34. National Institute for Health and Care Excellence (NICE). Lung cancer (non-small cell, second line) – erlotinib and gefitinib (revision of TA162 and TA175) (ID620) Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175): appraisal consultation document 2015. London, United Kingdom 2015 https://www.nice.org.uk/guidance/GID-TAG347/documents/erlotinib-and-gefitinib-fortreating-nonsmallcell-lung-cancer-that-has-progressed-followingprior-chemotherapy-review-of-ta162-and-ta175-appraisal-consultation-document. Accessed October 1, 2015
35. University Health Network (UHN). Pharmacy Department (personal communication) Toronto, Ontario, Canada: Pharmacy Department, 2015
36. McGill Health Sciences Centre. Pharmacy Department (personal communication) Montreal, Ontario, Canada: Pharmacy Department, 2015
37. Dranitsaris G, Evans WK, Milliken D, et al. The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer. J Eval Clin Pract 2005;11:350–6
38. Dranitsaris G, Cottrell W, Evans WK. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Curr Opin Oncol 2002;14:375–83
39. Dranitsaris G, Beegle N, Ravelo A, et al. Evaluating the impact of bevacizumab maintenance therapy on overall survival in advanced non-small-cell lung cancer. Clin Lung Cancer 2013;14:120–7
40. Solem C, Penrod J, Lees M, et al. Resource Utilization Among Advanced Squamous and non-Squamous non-Small Cell Lung Cancer Patients Receiving Second-Line Treatment in France, Germany, Italy, and Spain: Results of A Retrospective Medical Chart Review 2015. http://www.europeancancercongress.org/Scientific-Programme/Abstract-search#">http://www.europeancancercongress. org/Scientific-Programme/Abstract-search#http://www.poster-submission. com/ecc2015/visitors/carousel. 2015 Volume 18, Issue 7, Page A450 Accessed October 1, 2015
41. Gettinger S, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004–12
42. Rizvi N, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257–65
43. Canadian Agency for Drugs and Technologies in Health (CADTH). pan-Canadian oncology drug review: final economic guidance report (Pemetrexed (Alimta) for non-squamous non-small cell lung cancer). 2013. Ottawa, Ontario, Canada https://www.cadth.ca/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-egr.pdf. Accessed October 1, 2015
44. CADTH. pCODR final economic guidance report: crizotinib for advanced non-small cell lung cancer. 2013 Ottawa, Ontario, Canada
45. CADTH. pCODR expert review committee final recommendation: ipilimumab for melanoma. 2012 Ottawa, Ontario, Canada
46. Canadian Agency for Drugs and Technologies in Health (CADTH). pan-Canadian oncology drug review: final economic guidance report (Ipilimumab (Yervoy) for Advanced Melanoma). 2012. Ottawa, Ontario, Canada https://www.cadth.ca/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-egr.pdf. Accessed October 1, 2015
47. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: table 15.30 cancer of the lung and bronchus (invasive): percent distribution and counts by histology among histologically confirmed cases, 2008-2012, females by race. 2012. Bethesda, MD, USA http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL¼15&pageSEL¼sect_15_table.30. html. Accessed October 1, 2015
48. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Table 15.29: cancer of the lung and bronchus (Invasive) - Percent distribution and counts by histology among histologically confirmed cases, 2008-2012; males by race. 2012. Bethesda, MD, USA http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL¼15&pageSEL¼sect_15_table.29. html. Accessed October 1, 2015
49. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Table 15.28: Cancer of the lung and bronchus (Invasive) - Percent distribution and counts by histology among histologically confirmed cases, 2008-2012; both sexes by race. 2012. Bethesda, MD, USA http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL¼15&pageSEL¼sect_15_table.28.html. Accessed October 1, 2015